Skip to main content
Erschienen in: Japanese Journal of Radiology 3/2016

01.03.2016 | Original Article

Diagnostic and prognostic value of 18F-FDG PET/CT for axillary lymph node staging in patients with breast cancer

verfasst von: Kazuhiro Kitajima, Kazuhito Fukushima, Yasuo Miyoshi, Takayuki Katsuura, Yoko Igarashi, Yusuke Kawanaka, Miya Mouri, Kaoru Maruyama, Toshiko Yamano, Hiroshi Doi, Koichiro Yamakado, Seiichi Hirota, Shozo Hirota

Erschienen in: Japanese Journal of Radiology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the diagnostic and prognostic value of 18F-FDG-PET/CT for axillary lymph node (LN) staging in breast cancer patients, employing histologic evaluation as the reference.

Methods

Among 196 patients with biopsy-proven breast cancer who had undergone 18F-FDG-PET/CT before mastectomy or breast-conserving surgery with sentinel LN biopsy and/or axillary LN dissection, 200 axillae were retrospectively analyzed by visual assessment and quantitatively using SUVmax. LN SUVmax as well as other clinicopathological features were assessed for their prognostic value using the log-rank test and Cox method.

Results

Metastasis was diagnosed histopathologically in 56 (28 %) axillae. The sensitivity, specificity, and accuracy of visual PET/CT for diagnosing node metastasis were 55.4, 95.8, and 84.5 %, respectively. When the optimal discriminative SUVmax cutoff was 1.5, these figures were 51.8, 97.2, and 84.5 %, respectively. Fourteen of 55 patients (25.5 %) with LN metastases suffered a recurrence during follow-up (median 39 months). Patients with a high nodal SUVmax (≥1.7) had a significantly lower progression-free survival rate than those with a low SUVmax (p = 0.0499). Axillary nodal and primary tumor SUVmax as well as estrogen receptor status were significantly associated with recurrence.

Conclusion

Axillary nodal SUVmax may be a prognostic indicator of disease recurrence in patients with axillary LN metastases.
Literatur
1.
2.
Zurück zum Zitat Arriagada R, Le MG, Dunant A, Tubiana M, Contesso G. Twenty-five years of follow-up in patients with operable breast carcinoma: correlation between clinicopathologic factors and the risk of death in each 5-year period. Cancer. 2006;106:743–50.CrossRefPubMed Arriagada R, Le MG, Dunant A, Tubiana M, Contesso G. Twenty-five years of follow-up in patients with operable breast carcinoma: correlation between clinicopathologic factors and the risk of death in each 5-year period. Cancer. 2006;106:743–50.CrossRefPubMed
3.
Zurück zum Zitat Wahl RL, Siegel BA, Coleman RE. Gatsonis CG; PET Study Group. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol. 2004;22:277–85.CrossRefPubMed Wahl RL, Siegel BA, Coleman RE. Gatsonis CG; PET Study Group. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol. 2004;22:277–85.CrossRefPubMed
4.
Zurück zum Zitat Gil-Rendo A, Zornoza G, García-Velloso MJ, Regueira FM, Beorlegui C, Cervera M. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg. 2006;93:707–12.CrossRefPubMed Gil-Rendo A, Zornoza G, García-Velloso MJ, Regueira FM, Beorlegui C, Cervera M. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg. 2006;93:707–12.CrossRefPubMed
5.
Zurück zum Zitat Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol. 2007;18:473–8.CrossRefPubMed Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol. 2007;18:473–8.CrossRefPubMed
6.
Zurück zum Zitat Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26:4746–51.CrossRefPubMed Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26:4746–51.CrossRefPubMed
7.
Zurück zum Zitat Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, Kondo N, et al. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer. 2008;9:165–74.CrossRef Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, Kondo N, et al. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer. 2008;9:165–74.CrossRef
8.
Zurück zum Zitat Kim J, Lee J, Chang E, Kim S, Suh K, Sul J, et al. Selective sentinel node plus additional non-sentinel node biopsy based on an FDG-PET/CT scan in early breast cancer patients: single institutional experience. World J Surg. 2009;33:943–9.CrossRefPubMed Kim J, Lee J, Chang E, Kim S, Suh K, Sul J, et al. Selective sentinel node plus additional non-sentinel node biopsy based on an FDG-PET/CT scan in early breast cancer patients: single institutional experience. World J Surg. 2009;33:943–9.CrossRefPubMed
9.
Zurück zum Zitat Taira N, Ohsumi S, Takabatake D, Hara F, Takashima S, Aogi K, et al. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging. Jpn J Clin Oncol. 2009;39:16–21.CrossRefPubMed Taira N, Ohsumi S, Takabatake D, Hara F, Takashima S, Aogi K, et al. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging. Jpn J Clin Oncol. 2009;39:16–21.CrossRefPubMed
10.
Zurück zum Zitat Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36:1543–50.CrossRefPubMed Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36:1543–50.CrossRefPubMed
11.
Zurück zum Zitat Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426–35.CrossRefPubMed Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426–35.CrossRefPubMed
12.
Zurück zum Zitat Choi YJ, Shin YD, Kang YH, Lee MS, Lee MK, Cho BS, et al. The effects of preoperative 18F-FDG PET/CT in breast cancer patients in comparison to the conventional imaging study. J Breast Cancer. 2012;15:441–8. Choi YJ, Shin YD, Kang YH, Lee MS, Lee MK, Cho BS, et al. The effects of preoperative 18F-FDG PET/CT in breast cancer patients in comparison to the conventional imaging study. J Breast Cancer. 2012;15:441–8.
13.
Zurück zum Zitat Pritchard KI, Julian JA, Holloway CM, McCready D, Gulenchyn KY, George R, et al. Prospective study of 2-[18F] fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario Clinical Oncology Group study. J Clin Oncol. 2012;30:1274–9. Pritchard KI, Julian JA, Holloway CM, McCready D, Gulenchyn KY, George R, et al. Prospective study of 2-[18F] fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario Clinical Oncology Group study. J Clin Oncol. 2012;30:1274–9.
14.
Zurück zum Zitat Zhang X, Wu F, Han P. The role of 18F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited. Hell J Nucl Med. 2014;17:177–83.PubMed Zhang X, Wu F, Han P. The role of 18F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited. Hell J Nucl Med. 2014;17:177–83.PubMed
15.
Zurück zum Zitat Robertson IJ, Hand F, Kell MR. FDG-PET/CT in the staging of local/regional metastases in breast cancer. Breast. 2011;20:491–4.CrossRefPubMed Robertson IJ, Hand F, Kell MR. FDG-PET/CT in the staging of local/regional metastases in breast cancer. Breast. 2011;20:491–4.CrossRefPubMed
16.
Zurück zum Zitat Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008;38:250–8.CrossRefPubMed Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008;38:250–8.CrossRefPubMed
17.
Zurück zum Zitat Song BI, Hong CM, Lee HJ, et al. Prognostic value of primary tumor uptake on F-18 FDG PET/CT in patients with invasive ductal breast cancer. Nucl Med Mol Imaging. 2011;45:117–24.CrossRefPubMedPubMedCentral Song BI, Hong CM, Lee HJ, et al. Prognostic value of primary tumor uptake on F-18 FDG PET/CT in patients with invasive ductal breast cancer. Nucl Med Mol Imaging. 2011;45:117–24.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Kadoya T, Aogi K, Kiyoto S, Masumoto N, Sugawara Y, Okada M. Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study. Breast Cancer Res Treat. 2013;141:269–75.CrossRefPubMedPubMedCentral Kadoya T, Aogi K, Kiyoto S, Masumoto N, Sugawara Y, Okada M. Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study. Breast Cancer Res Treat. 2013;141:269–75.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Song BI, Lee SW, Jeong SY, Chae YS, Lee WK, Ahn BC, et al. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer. J Nucl Med. 2012;53:1337–44.CrossRefPubMed Song BI, Lee SW, Jeong SY, Chae YS, Lee WK, Ahn BC, et al. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer. J Nucl Med. 2012;53:1337–44.CrossRefPubMed
20.
Zurück zum Zitat Murase K, Yanai A, Saito M, Imamura M, Miyagawa Y, Takatsuka Y, et al. Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers. Breast Cancer. 2014;21:52–7.CrossRefPubMed Murase K, Yanai A, Saito M, Imamura M, Miyagawa Y, Takatsuka Y, et al. Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers. Breast Cancer. 2014;21:52–7.CrossRefPubMed
21.
Zurück zum Zitat McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18:2560–6.PubMed McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18:2560–6.PubMed
22.
Zurück zum Zitat Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932–45.CrossRefPubMed Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932–45.CrossRefPubMed
23.
Zurück zum Zitat Bundschuh RA, Essler M, Dinges J, Berchtenbreiter C, Mariss J, Martínez-Möller A, et al. Semiautomatic algorithm for lymph node analysis corrected for partial volume effects in combined positron emission tomography-computed tomography. Mol Imaging. 2010;9:319–28.PubMed Bundschuh RA, Essler M, Dinges J, Berchtenbreiter C, Mariss J, Martínez-Möller A, et al. Semiautomatic algorithm for lymph node analysis corrected for partial volume effects in combined positron emission tomography-computed tomography. Mol Imaging. 2010;9:319–28.PubMed
Metadaten
Titel
Diagnostic and prognostic value of 18F-FDG PET/CT for axillary lymph node staging in patients with breast cancer
verfasst von
Kazuhiro Kitajima
Kazuhito Fukushima
Yasuo Miyoshi
Takayuki Katsuura
Yoko Igarashi
Yusuke Kawanaka
Miya Mouri
Kaoru Maruyama
Toshiko Yamano
Hiroshi Doi
Koichiro Yamakado
Seiichi Hirota
Shozo Hirota
Publikationsdatum
01.03.2016
Verlag
Springer Japan
Erschienen in
Japanese Journal of Radiology / Ausgabe 3/2016
Print ISSN: 1867-1071
Elektronische ISSN: 1867-108X
DOI
https://doi.org/10.1007/s11604-015-0515-1

Weitere Artikel der Ausgabe 3/2016

Japanese Journal of Radiology 3/2016 Zur Ausgabe

Acknowledgment

Acknowledgment

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.